PMC:7321036 / 909-1184 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T21","span":{"begin":23,"end":35},"obj":"GO:0065007"},{"id":"T22","span":{"begin":67,"end":80},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T23","span":{"begin":99,"end":102},"obj":"PR:000008220"},{"id":"T24","span":{"begin":193,"end":201},"obj":"SP_7"},{"id":"T77793","span":{"begin":23,"end":35},"obj":"GO:0065007"},{"id":"T44088","span":{"begin":67,"end":80},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T2452","span":{"begin":99,"end":102},"obj":"PR:000008220"},{"id":"T31032","span":{"begin":193,"end":201},"obj":"SP_7"}],"text":"horylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":193,"end":201},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"horylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":150,"end":159},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"horylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis "}

{"project":"LitCovid-PubTator","denotations":[{"id":"18","span":{"begin":99,"end":102},"obj":"Gene"},{"id":"19","span":{"begin":114,"end":117},"obj":"Gene"},{"id":"30","span":{"begin":193,"end":201},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Gene:5594"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Gene:558"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"horylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis "}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":58,"end":212},"obj":"Sentence"},{"id":"T9","span":{"begin":214,"end":232},"obj":"Sentence"},{"id":"T10","span":{"begin":234,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"horylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.\n\nGraphical Abstract\n\nHighlights\n• Phosphoproteomics analysis "}